se of brain perfusion SPECT to determine responder to choline esterase inhibitor to reduce national therapeutic cost

Phase 4

Completed

• Conditions: s disease; s disease response to donepezil; Alzheimer&#39

• Registration Number: TCTR20140901001
• Lead Sponsor: government

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09-01
• Study Completion: 2014-09-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Diagnosis of probable Alzheimer's disease by NINCDS/ADRDA criteria, mild to moderate degree

Exclusion Criteria

Severe head trauma, delirium, depression, other known neuro-psychologic diseases, COPD, asthma, sik sinus syndrome, ischemic heart disease, peptic ulcer, history of gastrointestinal bleeding, type I DM, had received choline esterase inhibitors or nicergoline or other research drugs within 1 month before the study, alcohol or drug abuse, during treatment with NSAIDs, anticholinergic, carrbamazepine, dexamethasone, phenobarbital, ketoconazole

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cognitive function 0,3,6 months cognitive battery tests

Secondary Outcome Measures

Name	Time	Method
brain perfusion SPECT change 0,4 hr, 15 days, 3 months brain perfusion SPECT